CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
DURHAM, N.C., Aug. 30, 2011 /PRNewswire-iReach/ — CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has raised $7.5 million of a planned $9.5 million convertible note financing from its existing investors to support further late stage development of lasmiditan. Participating in the financing were Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.